As gastric cancer reveals more heterogeneity in the expression of erbB2 than breast cancer, a modified scoring system for gastric cancer was agreed upon at an international consensus meeting [11], and used by the panel of pathologists in the ToGA study. This evidence concerns the gene ERBB2 and breast carcinoma.